Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing dienogest and estradiol valerate: a randomized controlled trial

M. RAPS, F Rosendaal, F.R. Rosendaal, B Ballieux, Bart E.P.B. Ballieux, Jan Rosing, J Rosing, S Thomassen, Stella Thomassen, Frans M. Helmerhorst, F Helmerhorst, Huib van Vliet, H. van Vliet
Journal of thrombosis and haemostasis : JTH · 2013 · vol. 11(5) , pp. 855–861 · doi:10.1111/jth.12172 · PMID:23410231 · W2143669425
RCT OA: bronze CC0 ⤵ 7 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This randomized controlled trial investigated resistance to and levels of APC and SHBG in women using a four-phasic oral contraceptive containing dienogest and estradiol valerate.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: The use of combined oral contraceptives is associated with a 3- to 6-fold increased risk of venous thrombosis. This increased risk depends on the estrogen dose as well as the progestogen type of combined oral contraceptives. Thrombin generation-based activated protein C resistance (APC resistance) and sex hormone-binding globulin (SHBG) levels predict the thrombotic risk of a combined hormonal contraceptive. Recently, a four-phasic oral contraceptive containing dienogest (DNG) and estradiol valerate (E2V) has been marketed. The aim of this study was to evaluate the thrombotic risk of the DNG/E2V oral contraceptive by comparing APC resistance by measuring normalized APC sensitivity ratios (nAPCsr) and SHBG levels in users of oral contraceptives containing dienogest and estradiol valerate (DNG/E2V) and oral contraceptives containing levonorgestrel and ethinyl estradiol (LNG/EE). METHODS: We conducted a single-center, randomized, open label, parallel-group study in 74 women using DNG/E2V or LNG/EE, and measured nAPCsr and SHBG levels in every phase of the regimen of DNG/E2V. RESULTS: During the pill cycle SHBG levels did not differ between DNG/E2V users and LNG/EE users. nAPCsr levels were overall slightly lower in DNG/E2V users than in LNG/EE users, mean difference -0.44 (95% CI, -1.04 to 0.17) for day 2, -0.20 (95% CI, -0.76 to 0.37) for day 7, -0.27 (95% CI, -0.81 to 0.28) for day 24 and -0.34 (95% CI, -0.91 to 0.24) for day 26. CONCLUSION: No statistical significant differences in nAPCsr and SHBG levels were found between users of the oral contraceptive containing DNG/E2V and LNG/EE, suggesting a comparable thrombotic risk.

My notes (saved in your browser only)

MeSH descriptors

Activated Protein C Resistance Contraceptives, Oral, Combined Estradiol Nandrolone Sex Hormone-Binding Globulin Activated Protein C Resistance Adolescent Adult Contraceptives, Oral, Combined Estradiol Estradiol Female Humans Nandrolone Nandrolone Sex Hormone-Binding Globulin Young Adult

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (33)

Cited by (6)

Source provenance

openalex
last seen: 2026-05-11T06:37:04.871248+00:00
pubmed
last seen: 2026-10-08T21:11:31.379484+00:00
License: CC0 · commercial use OK